Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
暂无分享,去创建一个
Martin Hellmich | Qing Qiao | Jaakko Tuomilehto | Walter Lehmacher | W. Lehmacher | M. Hellmich | J. Tuomilehto | J. Lindström | Markku Peltonen | J. Chiasson | Q. Qiao | Jean-Louis Chiasson | Markku Peltonen | Jaana Lindström | Andreas Brückner | Torsten Westermeier | Thomas Evers | Andreas Brückner | T. Evers | T. Westermeier
[1] Stefan R Bornstein,et al. An Accurate Risk Score Based on Anthropometric, Dietary, and Lifestyle Factors to Predict the Development of Type 2 Diabetes , 2007, Diabetes Care.
[2] Ralph B D'Agostino,et al. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. , 2005, Statistics in medicine.
[3] Markolf Hanefeld,et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.
[4] Heejung Bang,et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. , 2005, Diabetes care.
[5] Mark Woodward,et al. A Risk Score for Predicting Incident Diabetes in the Thai Population A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.
[6] T. Valle,et al. Prevalence of diabetes and impaired glucose regulation in 45‐ to 64‐year‐old individuals in three areas of Finland , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[7] J. Tuomilehto,et al. The major diabetes prevention trials , 2003, Current diabetes reports.
[8] N. Wareham,et al. Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice , 2000, Diabetes/metabolism research and reviews.
[9] J Tuomilehto,et al. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. , 2007, Diabetes research and clinical practice.
[10] N. Pronk,et al. Identifying individuals at risk for the development of type 2 diabetes mellitus. , 2003, The American journal of managed care.
[11] T. Valle,et al. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[12] Tamara Harris,et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. , 2005, Diabetes care.
[13] Jean Tichet,et al. Predicting Diabetes: Clinical, Biological, and Genetic Approaches , 2008, Diabetes Care.
[14] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[15] M. Engelgau,et al. Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. , 2004, Diabetes technology & therapeutics.
[16] J. Tuomilehto,et al. The European Perspective on Diabetes Prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE) , 2007, Diabetes & vascular disease research.
[17] M. Laakso,et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. , 1998, Diabetes care.
[18] L. Bouter,et al. Performance of an NIDDM Screening Questionnaire Based on Symptoms and Risk Factors , 1997, Diabetes Care.
[19] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[20] Jaakko Tuomilehto,et al. Determinants for the Effectiveness of Lifestyle Intervention in the Finnish Diabetes Prevention Study , 2008, Diabetes Care.
[21] S. Haffner,et al. Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.
[22] J. Tuomilehto,et al. The European perspective of type 2 diabetes prevention: diabetes in Europe--prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[23] J M Dekker,et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. , 2001, JAMA.
[24] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[25] P. Zimmet,et al. Diagnosis and classification of diabetes mellitus , 2002 .
[26] M. Harris,et al. Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.
[27] GerdAssmann,et al. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002 .
[28] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[29] R. Jackson,et al. Updated New Zealand cardiovascular disease risk-benefit prediction guide , 2000, BMJ : British Medical Journal.
[30] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[31] M. Engelgau,et al. A New and Simple Questionnaire to Identify People at Increased Risk for Undiagnosed Diabetes , 1995, Diabetes Care.
[32] Richard Kahn,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.
[33] M. Laakso,et al. The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data , 1998, Diabetes Care.
[34] Jaakko Tuomilehto,et al. The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.
[35] Bendix Carstensen,et al. A Danish diabetes risk score for targeted screening: the Inter99 study. , 2004, Diabetes care.
[36] Aziz Sheikh,et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore , 2009, BMJ : British Medical Journal.
[37] J. Lindström,et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.
[38] M. Laakso,et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.
[39] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[40] Hilkka Soininen,et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.
[41] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[42] P. Zimmet. The burden of type 2 diabetes: are we doing enough? , 2003, Diabetes & Metabolism.
[43] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[44] V. Mohan,et al. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. , 2005, The Journal of the Association of Physicians of India.
[45] R. Holle,et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. , 2005, Archives of internal medicine.
[46] J. Shaw,et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[47] R. D'Agostino,et al. Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.